Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Cymbalta

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
  • S. Gaw, B. Brooks
  • Environmental toxicology and chemistry
  • 2016
  • Corpus ID: 5148655
Pharmaceuticals are ubiquitous contaminants in aquatic ecosystems. Adaptive monitoring, assessment, and management programs will… Expand
  • figure 1
2012
2012
To the Editor: Serotonin syndrome [1,2] is caused by stimulation of a subset of serotonin receptors in the brainstem and spinal… Expand
  • table 1
  • table 2
Review
2009
Review
2009
  • J. Davidson
  • The Journal of clinical psychiatry
  • 2009
  • Corpus ID: 10847000
Many patients with generalized anxiety disorder (GAD) do not receive adequate treatment. Several classes of drugs, including… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • table 2
Review
2009
Review
2009
  • M. Pollack
  • The Journal of clinical psychiatry
  • 2009
  • Corpus ID: 41616491
Generalized anxiety disorder (GAD) has a lifetime prevalence in the US population of about 5.7%. Typically, GAD begins in early… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2009
Highly Cited
2009
Milnacipran (Savella) inhibits both norepinephrine and serotonin reuptake and is distinguished by a nearly 3-fold greater potency… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
2008
2008
  • D. Goldenberg
  • Primary care companion to the Journal of clinical…
  • 2008
  • Corpus ID: 33169218
effects of fibromyalgia on cognition. Specific pharmacologic treatment recommendations were given by Daniel J. Clauw, M.D., while… Expand
  • table 1
  • table 2
  • figure 1
Review
2007
Review
2007
Abstract:  “Burning mouth syndrome” (BMS) refers to a chronic orofacial pain disorder usually unaccompanied by mucosal lesions or… Expand
Highly Cited
2006
Highly Cited
2006
Duloxetine (Cymbalta) is manufactured by Eli Lilly and Company and is the newest antidepressant to be approved by the Food and… Expand
  • figure 1
  • table I
  • table I
  • figure 2
  • figure 3
2005
2005
  • The Medical letter on drugs and therapeutics
  • 2005
  • Corpus ID: 44978751
A selective serotonin and norepinephrine reuptake inhibitor approved for depression and now also for diabetic peripheral… Expand
Highly Cited
2003
Highly Cited
2003
A series of naphthalenyloxy-arylpropylamines have been prepared and are demonstrated to be inhibitors of both serotonin and… Expand